Compare · LFCR vs NVO
LFCR vs NVO
Side-by-side comparison of Lifecore Biomedical Inc. (LFCR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LFCR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 712.4x LFCR ($243.8M).
- Over the past year, LFCR is down 3.8% and NVO is down 30.4% - LFCR leads by 26.6 points.
- LFCR has been more active in the news (5 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 6 for LFCR).
- Company
- Lifecore Biomedical Inc.
- Novo Nordisk A/S
- Price
- $6.38-0.78%
- $38.82-1.05%
- Market cap
- $243.8M
- $173.66B
- 1M return
- +42.89%
- -10.14%
- 1Y return
- -3.77%
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 5
- 3
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LFCR
- Lifecore Biomedical to Participate at Upcoming Industry Conferences
- Lifecore Biomedical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form DEFA14A filed by Lifecore Biomedical Inc.
- Lifecore Biomedical Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Lifecore Biomedical to be Acquired by Webster Equity Partners
- Lifecore Biomedical to Participate at CPHI Global Conference
- Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
- SEC Form 10-Q filed by Lifecore Biomedical Inc.
- Lifecore Biomedical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank